|
Status |
Public on May 21, 2019 |
Title |
Gene expression profiling of primary HER2-positive breast cancers before and after brief exposure to single agent neoadjuvant trastuzumab |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
Tumor incisional biopsies were obtained at baseline and after brief-exposure to single-agent trastuzumab from patients enrolled on the TRastuzumab-UPfront-in-HER2-positive-locally-advanced- BC (TRUP) window-of-opportunity trial. Gene expression profiling was conducted on these tumor biopsies to identify transcriptional features at baseline and changes upon brief-exposure to trastuzumab associated with response to short term trastuzumab and the complete pre-operative therapy
|
|
|
Overall design |
Gene expression profiling was performed using RNA from frozen core biopsies from 17 patients with primary HER2-positive (HER2+) tumors before and after brief-exposure treatment with single agent neoadjuvant trastuzumab.
|
|
|
Contributor(s) |
De Cecco L, Triulzi T |
Citation(s) |
30478407 |
|
Submission date |
May 06, 2018 |
Last update date |
May 21, 2019 |
Contact name |
Loris De Cecco |
E-mail(s) |
loris.dececco@istitutotumori.mi.it
|
Organization name |
IRCSS Istituto Nazionale Tumori
|
Street address |
via Venezian 1
|
City |
Milan |
ZIP/Postal code |
20133 |
Country |
Italy |
|
|
Platforms (1) |
GPL14951 |
Illumina HumanHT-12 WG-DASL V4.0 R2 expression beadchip |
|
Samples (34)
|
|
Relations |
BioProject |
PRJNA464245 |